PharmaVoice - Latest News

Pfizer’s Paxlovid flunks long COVID study as researchers uncover the condition’s deep toll

Meagan Parrish — Fri, 14 Jun 2024 08:00:00 -0400

While researchers gain ground understanding long COVID’s impact, viable treatments could still be a long way off.

Regenxbio CEO to step down after 15 years

Ned Pagliarulo — Thu, 13 Jun 2024 12:00:00 -0400

Kenneth Mills will become chair of the gene therapy developer's board while Curran Simpson, the current chief operating officer, will take his place as company head.

Lilly’s adcomm win shows amyloid and tau will likely dominate Alzheimer’s — for now

Michael Gibney — Thu, 13 Jun 2024 08:00:00 -0400

Lilly is the latest to approach the coveted Alzheimer’s approval, but a slate of drugmakers are lining up clinical trials in amyloid and tau to take a shot at improving patient outcomes.

Behind the powerful computations, AI’s role in pharma is still beset by challenges

Amy Baxter — Wed, 12 Jun 2024 08:00:00 -0400

Small biotechs are saving time and money leveraging AI to develop new drugs, but incomplete data and disease complexity remain hurdles for the space.

Despite adcomm rejection, Lykos CEO sees future for MDMA drug

Alexandra Pecci — Wed, 12 Jun 2024 08:00:00 -0400

Although the rebuff makes approval “a bit more challenging,” Lykos is moving forward with the psychedelic-based treatment for PTSD.

FDA’s platform designation aims to ease R&D pain points

Amy Baxter — Tue, 11 Jun 2024 08:00:00 -0400

A new program creates approval pathways for multiple drugs developed on the same platform.

As Big Pharma places bigger bets on ADCs, here’s where the field is headed next

Michael Gibney — Tue, 11 Jun 2024 08:00:00 -0400

With more drugmakers getting into the antibody-drug conjugate game, emerging innovations signal a bright future for the technology.

Behind Big Pharma’s layoffs — is there an end in sight?

Kelly Bilodeau — Mon, 10 Jun 2024 08:00:00 -0400

A slew of major companies, including BMS, have announced cost-cutting measures in recent months. What will it take to turn the tide?

Pharma’s R&D gamble: picking pipeline winners in a risky field

Meagan Parrish — Fri, 07 Jun 2024 08:00:00 -0400

How leaders from biotech, Big Pharma and the investment world know when they've found the right candidate or company to back.

A ‘widening gap’ in access to new cancer meds drives efforts from City of Hope and Bristol Myers

Michael Gibney — Thu, 06 Jun 2024 08:00:00 -0400

Cancer care is improving so quickly that receiving newer medications can be difficult — City of Hope’s wide oncology network and a 10-year commitment from Bristol Myers Squibb offer some solutions.